Hairy Cell Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 81 Published: August 30, 2022 Report Code: GDGMDHC22282IDB

 Hairy cell leukemia is a rare, slow-growing cancer of the blood in which bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection. Symptoms include fatigue, easy bruising, recurring infections, weakness and weight loss. Risk factors include exposure to radiation, chemicals and saw dust. Treatment includes surgery, chemotherapy and radiation therapy.

The Hairy Cell Leukemia pipeline drugs market research report outlays comprehensive information on the Hairy Cell Leukemia targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type, that are being developed by companies/universities. It also reviews key players involved in Hairy Cell Leukemia targeted therapeutics development with respective active and dormant or discontinued projects.

Hairy Cell Leukemia Pipeline Drugs Market Segmentation by Targets

Some of the primary targets in the Hairy Cell Leukemia pipeline drugs market are Cells Expressing B Lymphocyte Antigen CD19, Cells Expressing B Cell Receptor CD22, Cells Expressing B Lymphocyte Antigen CD20, Serine/Threonine Protein Kinase B Raf, Tyrosine Protein Kinase BTK, Dual Specificity Mitogen Activated Protein Kinase Kinase 1, Dual Specificity Mitogen Activated Protein Kinase Kinase 2, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform, B Cell Lymphoma 2, and CD3.

Hairy Cell Leukemia Pipeline Drugs Market Analysis, by Targets

Hairy Cell Leukemia Pipeline Drugs Market Analysis, by Targets

To know more about the targets in the Hairy Cell Leukemia pipeline drugs market, download a free report sample

Hairy Cell Leukemia Pipeline Drugs Market Segmentation by Mechanisms of Action

The primary mechanisms of action in the Hairy Cell Leukemia pipeline drugs market are Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, Cytotoxic To Cells Expressing B Cell Receptor CD22, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, Serine/Threonine Protein Kinase B Raf Inhibitor, Tyrosine Protein Kinase BTK Inhibitor, Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Inhibitor, Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Inhibitor, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor, B Cell Lymphoma 2 Inhibitor, and CD3 Agonist.

Hairy Cell Leukemia Pipeline Drugs Market Analysis, by Mechanisms of Action

Hairy Cell Leukemia Pipeline Drugs Market Analysis, by Mechanisms of Action

To know more about the MoA in the Hairy Cell Leukemia pipeline drugs market, download a free report sample

Hairy Cell Leukemia Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Hairy Cell Leukemia pipeline drugs market are Oral, Intravenous, Parenteral, Intralesional, and Subcutaneous.

Hairy Cell Leukemia Pipeline Drugs Market Analysis, by Routes of Administration

Hairy Cell Leukemia Pipeline Drugs Market Analysis, by Routes of Administration

To know more about the RoA in the Hairy Cell Leukemia pipeline drugs market, download a free report sample

Hairy Cell Leukemia Pipeline Drugs Market Segmentation by Molecule Type

The key molecule types in the Hairy Cell Leukemia pipeline drugs market are Gene-Modified Cell Therapy, Small Molecule, Monoclonal Antibody, Biologic, Monoclonal Antibody Conjugated, and Recombinant Protein.

Hairy Cell Leukemia Pipeline Drugs Market Analysis, by Molecule Type

Hairy Cell Leukemia Pipeline Drugs Market Analysis, by Molecule Type

To know more about the molecule type in the Hairy Cell Leukemia pipeline drugs market, download a free report sample

Competitive Landscape

Some of the leading companies in the Hairy Cell Leukemia pipeline drugs market are F. Hoffmann-La Roche Ltd, Incyte Corp, Wuhan Bio-Raid Biotechnology Co Ltd, AstraZeneca Plc, AbbVie Inc, Ascentage Pharma Group International, Autolus Therapeutics Plc, Bristol-Myers Squibb Co, Eureka Therapeutics Inc, and Jecho Biopharmaceuticals Co Ltd.

Hairy Cell Leukemia Pipeline Drugs Market Analysis, by Leading Companies

Hairy Cell Leukemia Pipeline Drugs Market Analysis, by Leading Companies

To know more about the leading companies in the Hairy Cell Leukemia pipeline drugs market, download a free report sample

Hairy Cell Leukemia Pipeline Drugs Market Report Overview

Key Targets Cells Expressing B Lymphocyte Antigen CD19, Cells Expressing B Cell Receptor CD22, Cells Expressing B Lymphocyte Antigen CD20, Serine/Threonine Protein Kinase B Raf, Tyrosine Protein Kinase BTK, Dual Specificity Mitogen Activated Protein Kinase Kinase 1, Dual Specificity Mitogen Activated Protein Kinase Kinase 2, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform, B Cell Lymphoma 2, and CD3
Key Mechanisms of Action Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, Cytotoxic To Cells Expressing B Cell Receptor CD22, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, Serine/Threonine Protein Kinase B Raf Inhibitor, Tyrosine Protein Kinase BTK Inhibitor, Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Inhibitor, Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Inhibitor, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor, B Cell Lymphoma 2 Inhibitor, and CD3 Agonist
Key Routes of Administration Oral, Intravenous, Parenteral, Intralesional, and Subcutaneous
Key Molecule Types Gene-Modified Cell Therapy, Small Molecule, Monoclonal Antibody, Biologic, Monoclonal Antibody Conjugated, and Recombinant Protein
Key Companies F. Hoffmann-La Roche Ltd, Incyte Corp, Wuhan Bio-Raid Biotechnology Co Ltd, AstraZeneca Plc, AbbVie Inc, Ascentage Pharma Group International, Autolus Therapeutics Plc, Bristol-Myers Squibb Co, Eureka Therapeutics Inc, and Jecho Biopharmaceuticals Co Ltd

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hairy Cell Leukemia (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Hairy Cell Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hairy Cell Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hairy Cell Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hairy Cell Leukemia (Oncology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hairy Cell Leukemia (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hairy Cell Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Players

AbbVie Inc
Ascentage Pharma Group International
AstraZeneca Plc
Autolus Therapeutics Plc
Bristol-Myers Squibb Co
Eureka Therapeutics Inc
F. Hoffmann-La Roche Ltd
Incyte Corp
Jecho Biopharmaceuticals Co Ltd
MacroGenics Inc
Mediolanum farmaceutici SpA
Mustang Bio Inc
Novartis AG
Sorrento Therapeutics Inc
Wuhan Bio-Raid Biotechnology Co Ltd
Xi'An Yufan Biotechnology Co Ltd
Xynomic Pharmaceuticals Holdings Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hairy Cell Leukemia – Overview

Hairy Cell Leukemia – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hairy Cell Leukemia – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hairy Cell Leukemia – Companies Involved in Therapeutics Development

AbbVie Inc

Ascentage Pharma Group International

AstraZeneca Plc

Autolus Therapeutics Plc

Bristol-Myers Squibb Co

Eureka Therapeutics Inc

F. Hoffmann-La Roche Ltd

Incyte Corp

Jecho Biopharmaceuticals Co Ltd

MacroGenics Inc

Mediolanum farmaceutici SpA

Mustang Bio Inc

Novartis AG

Sorrento Therapeutics Inc

Wuhan Bio-Raid Biotechnology Co Ltd

Xi’An Yufan Biotechnology Co Ltd

Xynomic Pharmaceuticals Holdings Inc

Hairy Cell Leukemia – Drug Profiles

abivertinib maleate – Drug Profile

Product Description

Mechanism Of Action

History of Events

acalabrutinib maleate – Drug Profile

Product Description

Mechanism Of Action

History of Events

APG-2575 – Drug Profile

Product Description

Mechanism Of Action

History of Events

AUTO-1NG – Drug Profile

Product Description

Mechanism Of Action

History of Events

CDMO-002 – Drug Profile

Product Description

Mechanism Of Action

cobimetinib fumarate – Drug Profile

Product Description

Mechanism Of Action

History of Events

dabrafenib mesylate + trametinib dimethyl sulfoxide – Drug Profile

Product Description

Mechanism Of Action

History of Events

dezapelisib – Drug Profile

Product Description

Mechanism Of Action

History of Events

ELB-021 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ET-019002 – Drug Profile

Product Description

Mechanism Of Action

GEM-155 – Drug Profile

Product Description

Mechanism Of Action

Gene Therapy to Target CD19 for Leukemia or Lymphoma – Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy to Target CD19 for Lymphoma and Leukemia – Drug Profile

Product Description

Mechanism Of Action

Gene Therapy to Target CD19 for Oncology – Drug Profile

Product Description

Mechanism Of Action

Gene Therapy to Target CD19 for Oncology – Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy to Target CD19 for Oncology – Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy to Target CD20 for Oncology – Drug Profile

Product Description

Mechanism Of Action

Gene Therapy to Target CD22 for Oncology – Drug Profile

Product Description

Mechanism Of Action

Gene Therapy to Target CD22 for Oncology – Drug Profile

Product Description

Mechanism Of Action

History of Events

ibrutinib – Drug Profile

Product Description

Mechanism Of Action

History of Events

interferon alfa-2b – Drug Profile

Product Description

Mechanism Of Action

itacitinib adipate – Drug Profile

Product Description

Mechanism Of Action

History of Events

MB-106 – Drug Profile

Product Description

Mechanism Of Action

History of Events

MGD-024 – Drug Profile

Product Description

Mechanism Of Action

moxetumomab pasudotox – Drug Profile

Product Description

Mechanism Of Action

History of Events

obinutuzumab – Drug Profile

Product Description

Mechanism Of Action

History of Events

Onureg – Drug Profile

Product Description

Mechanism Of Action

History of Events

parsaclisib – Drug Profile

Product Description

Mechanism Of Action

History of Events

vemurafenib – Drug Profile

Product Description

Mechanism Of Action

History of Events

XP-102 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Hairy Cell Leukemia – Dormant Projects

Hairy Cell Leukemia – Discontinued Products

Hairy Cell Leukemia – Product Development Milestones

Featured News & Press Releases

Jul 21, 2021: Study: Ibrutinib effective treatment for difficult to treat forms of hairy cell leukemia

May 19, 2021: ESMO: BRAF inhibitor and Rituximab for the management of refractory or relapsed HCL

Dec 10, 2020: CHMP adopts a positive opinion for the medicinal product Lumoxiti for the treatment of relapsed or refractory hairy cell leukaemia

Jan 02, 2020: The European Medicines Agency accepts the regulatory submission for Lumoxiti in relapsed or refractory hairy cell leukemia

Dec 08, 2019: Innate Pharma highlights FDA-approved Lumoxiti at ASH 2019

Nov 07, 2019: Innate Pharma to share new long-term data on Lumoxiti at 2019 American Society of Hematology annual meeting

May 08, 2019: A patient’s 10-year journey to moxetumomab for hairy cell leukemia

Mar 12, 2019: Innate Pharma announces the appointment of Jennifer Butler appointed as executive vice president, general manager, US

Nov 27, 2018: AstraZeneca to present on Lumoxiti 2018 American Society of Hematology Annual Meeting

Nov 02, 2018: Novartis to present data on Dabrafenib and Trametinib combination at 2018 ASH annual meeting

Sep 17, 2018: AstraZeneca’s Lumoxiti secures FDA nod to treat hairy cell leukaemia

Jun 02, 2018: Moxetumomab Pasudotox Pivotal Data in Patients with Previously-Treated Hairy Cell Leukemia Presented at the 2018 ASCO Meeting

Apr 03, 2018: US FDA Accepts Biologics License Application for Moxetumomab Pasudotox in Hairy Cell Leukaemia

Oct 09, 2016: ESMO 2016: Vemurafenib Shows Clinical Benefit in Diverse BRAF V600-Mutated Tumours

May 16, 2013: AstraZeneca’s MedImmune Enrolls First Patient In Phase III Leukemia Trial Of Moxetumomab Pasudotox

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Hairy Cell Leukemia, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Hairy Cell Leukemia – Pipeline by AbbVie Inc, 2022

Hairy Cell Leukemia – Pipeline by Ascentage Pharma Group International, 2022

Hairy Cell Leukemia – Pipeline by AstraZeneca Plc, 2022

Hairy Cell Leukemia – Pipeline by Autolus Therapeutics Plc, 2022

Hairy Cell Leukemia – Pipeline by Bristol-Myers Squibb Co, 2022

Hairy Cell Leukemia – Pipeline by Eureka Therapeutics Inc, 2022

Hairy Cell Leukemia – Pipeline by F. Hoffmann-La Roche Ltd, 2022

Hairy Cell Leukemia – Pipeline by Incyte Corp, 2022

Hairy Cell Leukemia – Pipeline by Jecho Biopharmaceuticals Co Ltd, 2022

Hairy Cell Leukemia – Pipeline by MacroGenics Inc, 2022

Hairy Cell Leukemia – Pipeline by Mediolanum farmaceutici SpA, 2022

Hairy Cell Leukemia – Pipeline by Mustang Bio Inc, 2022

Hairy Cell Leukemia – Pipeline by Novartis AG, 2022

Hairy Cell Leukemia – Pipeline by Sorrento Therapeutics Inc, 2022

Hairy Cell Leukemia – Pipeline by Wuhan Bio-Raid Biotechnology Co Ltd, 2022

Hairy Cell Leukemia – Pipeline by Xi’An Yufan Biotechnology Co Ltd, 2022

Hairy Cell Leukemia – Pipeline by Xynomic Pharmaceuticals Holdings Inc, 2022

Hairy Cell Leukemia – Dormant Projects, 2022

Hairy Cell Leukemia – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for Hairy Cell Leukemia, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently Asked Questions

Some of the targets in the Hairy Cell Leukemia pipeline drugs market are Cells Expressing B Lymphocyte Antigen CD19, Cells Expressing B Cell Receptor CD22, Cells Expressing B Lymphocyte Antigen CD20, Serine/Threonine Protein Kinase B Raf, Tyrosine Protein Kinase BTK, Dual Specificity Mitogen Activated Protein Kinase Kinase 1, Dual Specificity Mitogen Activated Protein Kinase Kinase 2, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform, B Cell Lymphoma 2, and CD3.

The primary mechanism of action in the Hairy Cell Leukemia pipeline drugs market are Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, Cytotoxic To Cells Expressing B Cell Receptor CD22, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, Serine/Threonine Protein Kinase B Raf Inhibitor, Tyrosine Protein Kinase BTK Inhibitor, Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Inhibitor, Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Inhibitor, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor, B Cell Lymphoma 2 Inhibitor, and CD3 Agonist.

The routes of administration in the Hairy Cell Leukemia pipeline drugs market are Oral, Intravenous, Parenteral, Intralesional, and Subcutaneous.

The molecule types in the Hairy Cell Leukemia pipeline drugs market are Gene-Modified Cell Therapy, Small Molecule, Monoclonal Antibody, Biologic, Monoclonal Antibody Conjugated, and Recombinant Protein.

Some of the leading companies in the Hairy Cell Leukemia pipeline drugs market are F. Hoffmann-La Roche Ltd, Incyte Corp, Wuhan Bio-Raid Biotechnology Co Ltd, AstraZeneca Plc, AbbVie Inc, Ascentage Pharma Group International, Autolus Therapeutics Plc, Bristol-Myers Squibb Co, Eureka Therapeutics Inc, and Jecho Biopharmaceuticals Co Ltd.

$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about our multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.

Still undecided about purchasing this report?

Enquire Before Buying

Request a Free Sample

Testimonial

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods